IL2 and hepatocellular carcinoma: The possibility of localized intravesical administration has corroborated its role in bladder cancer, but BCG has also been investigated for the treatment of other cancer entities, with data in HCC limited to case reports, such as the successful therapy combination of BCG, IL-2 and melatonin (104).